Journals / Van Tıp Dergisi / 2018 / Cilt: 25 - Sayı: 4

Current Treatment of Chronic Hepatitis C Genotype 1

Kronik Hepatit C Genotip 1 de Güncel Tedavi

Pages
547–551
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The success rate of over 90-95% with new developments in treatment, is promising for the future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hepatitis C virus (HCV) causes both acute and chronic hepatitis.
📊
Key Findings & Data:Following acute HCV infection, chronic infection develops in about %80 of patients.
💡
Conclusion & Impact:The success rate of over 90-95% with new developments in treatment, is promising for the future.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hepatitis C virus (HCV) causes both acute and chronic hepatitis. Following acute HCV infection, chronic infection develops in about %80 of patients. In years, Chronic hepatitis C(CHC) can progress to cirrhosis, hepatocellular carcinoma (HCC) or may result in liver transplantation. It is one of the most common causes of liver transplantion in the world. Recently, the treatment of CHC has dramatically improved. The success rate of over 90-95% with new developments in treatment, is promising for the future.

Özet

Hepatit C virüsü (HCV) hem akut, hem de kronik hepatite sebep olur. Akut enfeksiyondan sonra hastaların yaklaşık %80’inde kronik enfeksiyon gelişir. Kronik hepatit C (KHC) yıllar içinde ilerleyici bir seyir izleyerek siroz, hepatosellüler karsinom (HCC) veya karaciğer transplantasyonu ile sonuçlanabilir. Dünyada karaciğer transplantasyonunun en sık nedenleri arasında yer alır. Son zamanlarda KHC tedavisinde veren baş döndürücü gelişmeler olmuştur. Yeni gelişmelerle %90 -95 in üzerinde başarı oranı sağlanmış olması gelecek için ümit vericidir.

🔖

Cite This Article

AYDIN, M., DÜLGER, A. C. (2018). Current Treatment of Chronic Hepatitis C Genotype 1. Van Tıp Dergisi, Cilt: 25 - Sayı: 4, 547–551. https://ajindex.com/articles/338744

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. He L F, Alling D, Popkin T et al. Determining the size of nonA non-B hepatitis by filtration. JInfect Dis 1987;156:636-640
  2. Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. Best Pract Res Clin Gastroenterol 2012;26:371-80. 3-Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4): 1333-42.
  3. Manns MP, McHutchson JG, Gordon SC et al.PEGPEG-interferon Alfa-2B plus ribavirin compared to interferon Alfa-2B plus Ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65 Lawitz E1, Poordad FF2, Pang PS et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial: Lancet. 2014 Feb 8;383(9916):515-23. doi: 10.1016/S0140-6736(13)62121-2. Epub 2013 Nov 5. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383:515. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146:736. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594. Poordad F, Hezode C, Trinh R, et al. ABT-450/rombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973.
  4. Ferenci P, Bernstein D, Lalezari J, et al. ABT- 450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983.
  5. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatmentnaive patients: the COSMOS randomised study. Lancet 2014; 384:1756. Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effe